<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Advances in Molecular Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Advances in Molecular Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Успехи молекулярной онкологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-805X</issn><issn publication-format="electronic">2413-3787</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">729</article-id><article-id pub-id-type="doi">10.17650/2313-805X-2024-11-4-54-65</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Effects of a novel HSP90 inhibitor on estrogen receptor α signaling pathways in breast cancer cells</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние нового ингибитора HSP90 на сигнальные пути рецептора эстрогенов α в клетках рака молочной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2974-9555</contrib-id><name-alternatives><name xml:lang="en"><surname>Scherbakov</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Щербаков</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Alexander Mikhailovich Scherbakov</p><p>24 Kashirskoe Shosse, 115522 Moscow</p><p>11 Bol’shaya Pirogovskaya St., 119021 Moscow</p></bio><bio xml:lang="ru"><p>Александр Михайлович Щербаков</p><p>115522 Москва, Каширское шоссе, 24</p><p>119021 Москва, ул. Большая Пироговская, 11</p></bio><email>alex.scherbakov.2010@ya.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1264-7405</contrib-id><name-alternatives><name xml:lang="en"><surname>Sorokin</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Сорокин</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, 115522 Moscow</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0809-3710</contrib-id><name-alternatives><name xml:lang="en"><surname>Salnikova</surname><given-names>D. I.</given-names></name><name xml:lang="ru"><surname>Сальникова</surname><given-names>Д. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, 115522 Moscow</p><p>47 Leninsky Prospekt, 119991 Moscow</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p><p>119991 Москва, Ленинский пр-кт, 47</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2694-5232</contrib-id><name-alternatives><name xml:lang="en"><surname>Gudkova</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Гудкова</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, 115522 Moscow</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6015-6619</contrib-id><name-alternatives><name xml:lang="en"><surname>Andreeva</surname><given-names>O. E.</given-names></name><name xml:lang="ru"><surname>Андреева</surname><given-names>О. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, 115522 Moscow</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4022-6058</contrib-id><name-alternatives><name xml:lang="en"><surname>Mikhaylova</surname><given-names>A. L.</given-names></name><name xml:lang="ru"><surname>Михайлова</surname><given-names>А. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>24 Kashirskoe Shosse, 115522 Moscow</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4256-6646</contrib-id><name-alternatives><name xml:lang="en"><surname>Varabyeva</surname><given-names>N. A.</given-names></name><name xml:lang="ru"><surname>Воробьева</surname><given-names>А. О.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>5/2 Akademika Kuprevicha St., 220084 Minsk</p></bio><bio xml:lang="ru"><p>220084 Минск, ул. Академика Купревича, 5/2</p></bio><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3640-0981</contrib-id><name-alternatives><name xml:lang="en"><surname>Piven</surname><given-names>Yu. A.</given-names></name><name xml:lang="ru"><surname>Пивень</surname><given-names>Ю. А.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>5/2 Akademika Kuprevicha St., 220084 Minsk</p></bio><bio xml:lang="ru"><p>220084 Минск, ул. Академика Купревича, 5/2</p></bio><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">G.F.Gauze Institute of New Antibiotics</institution></aff><aff><institution xml:lang="ru">ФГБУН «Научно-исследовательский институт по изысканию новых антибиотиков им. Г.Ф. Гаузе»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБУН «Институт органической химии им. Н.Д. Зелинского Российской академии наук»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus</institution></aff><aff><institution xml:lang="ru">ГНУ «Институт биоорганической химии Национальной академии наук Беларуси»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2024</year></pub-date><volume>11</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>54</fpage><lpage>65</lpage><history><date date-type="received" iso-8601-date="2024-12-09"><day>09</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-12-09"><day>09</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Scherbakov A.M., Sorokin D.V., Salnikova D.I., Gudkova M.V., Andreeva O.E., Mikhaylova A.L., Varabyeva N.A., Piven Y.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Щербаков А.М., Сорокин Д.В., Сальникова Д.И., Гудкова М.В., Андреева О.Е., Михайлова А.Л., Воробьева А.О., Пивень Ю.А.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Scherbakov A.M., Sorokin D.V., Salnikova D.I., Gudkova M.V., Andreeva O.E., Mikhaylova A.L., Varabyeva N.A., Piven Y.A.</copyright-holder><copyright-holder xml:lang="ru">Щербаков А.М., Сорокин Д.В., Сальникова Д.И., Гудкова М.В., Андреева О.Е., Михайлова А.Л., Воробьева А.О., Пивень Ю.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://umo.abvpress.ru/jour/article/view/729">https://umo.abvpress.ru/jour/article/view/729</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Heat shock proteins (HSP), also known as molecular chaperones, are a large family of proteins that play crucial roles in histogenesis, homeostasis, and the folding and functional regulation of numerous client proteins. Among them, HSP90 is a key player, particularly in supporting the growth of tumor cells. HSP90 impacts multiple carcinogenic signaling pathways, including BCR-ABL, Raf-1, AKT, human epidermal growth factor receptor 2 (ERBB2/HER2), hypoxia-inducible factor 1-α (HIF-1α), janus kinase 2 (JAK2), STAT3, p53, and estrogen receptor α (ERα). As a result, the search for new, selective inhibitors of this chaperone is a high priority in medicinal chemistry and oncology.<bold>Aim.</bold> To evaluate the antiproliferative activity of a novel HSP90 inhibitor, THB5T-1, on ERα-positive breast cancer cell lines and assess its anti-estrogenic potential and selectivity. <bold>Materials and methods.</bold> The study was conducted on hormone-dependent breast cancer cell lines MCF7 and T47D, along with the normal fibroblast line hFB-hTERT. The antiproliferative activity of THB5T-1 was measured using the MTT assay, while immunoblotting was employed to analyze the effects of HSP90 inhibition on cell signaling pathways. Anti-estrogenic activity was assessed in MCF7 cells via a reporter assay, and molecular modeling was used to construct a model of THB5T-1 interaction with the ligand-binding domain of ERα.<bold>Results.</bold> The half-maximal inhibitory concentration (IC50) of THB5T-1 was determined to be 4.3 μM for MCF7 cells and 5.6 μM for T47D cells. At a concentration of 25 μM, cell survival decreased to 20%. The selectivity index for THB5T-1 varied from 3.7 to 5.0 in different breast cancer cell lines. The compound’s effects on hormonal pathways in MCF7 cells, as observed via reporter assay and immunoblotting, were dose-dependent. These findings were further supported by molecular docking studies, showing THB5T-1 interaction with the ligand-binding domain of ERα. Additionally, the antiproliferative activity of THB5T-1 in MCF7 cells was associated with reduced expression of cell cycle regulators cyclin D1 and cyclin-dependent kinase 4 (CDK4). Significant efficacy of compound THB5T-1 in combination with a selective AKT inhibitor was revealed.<bold>Conclusion.</bold> Compound THB5T-1 demonstrated significant antiproliferative effects on ERα-positive breast cancer cells and exhibited high selectivity. Its anti-estrogenic effects highlight its potential as a selective inhibitor of the HSP90/ ERα/GREB1 pathway, effectively blocking ERα-mediated cell proliferation.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Белки теплового шока (heat shock proteins, HSP), также известные как молекулярные шапероны, представляют собой большое семейство белков, регулирующих процессы гистогенеза и гомеостаза, а также влияющих на фолдинг и функциональную активность множества клиентских белков. Особый интерес в этом семействе представляет шаперон 90 (HSP90), который значительно поддерживает рост злокачественных клеток. Он оказывает комплексное влияние на сигнальные пути канцерогенеза, включая BCR-ABL, Raf-1, AKT, рецептор эпидермального фактора роста человека 2-го типа (ERBB2/HER2), индуцируемый гипоксией фактор 1α (HIF-1α), янус-киназу 2 (JAK2), STAT3, p53 и рецептор эстрогена α (ERα). Именно поэтому поиск новых селективных ингибиторов этого шаперона является актуальной задачей медицинской химии и онкологии.<bold>Цель исследования</bold> – изучение антипролиферативной активности нового ингибитора HSP90 THB5T-1 на линиях клеток ERα-положительного рака молочной железы и оценка его антиэстрогенного потенциала и селективности.<bold>Материалы и методы.</bold> Исследование проводили на линиях гормонозависимых клеток рака молочной железы MCF7 и T47D и нормальных фибробластов hFB-hTERT. Антипролиферативную активность соединения определяли посредством МТТ-теста. Для анализа влияния ингибирования HSP90 на сигнальные пути клеток использовали иммуноблоттинг. Оценку антиэстрогенной активности THB5T-1 проводили в клетках MCF7 методом репортерного анализа. Для построения модели взаимодействия THB5T-1 с лигандсвязывающим доменом ERα применяли молекулярное моделирование.<bold>Результаты.</bold> Концентрация THB5T-1, необходимая для полумаксимального ингибирования роста клеток (IC<sub>50</sub>), составила 4,3 мкМ для линии MCF7 и 5,6 мкМ для линии T47D. Увеличение концентрации THB5T-1 до 25 мкМ приводило к снижению выживаемости клеток до 20 %. индекс селективности THB5T-1 для различных клеток рака молочной железы варьировал от 3,7 до 5 у.е. Влияние соединения THB5T-1 на гормональные пути в клетках MCF7, выявленное с помощью репортерного анализа и иммуноблоттинга, оказалось дозозависимым. Способность THB5T-1 напрямую связываться с ERα подтверждена данными молекулярного моделирования. Антипролиферативные эффекты THB5T-1 в клетках MCF7 ассоциированы со снижением экспрессии регуляторов клеточного цикла, таких как циклин D1 и циклинзависимая киназа 4 (CDK4). Также выявлена значительная эффективность соединения THB5T-1 в комбинации с селективным ингибитором AKT.<bold>Заключение.</bold> Соединение THB5T-1 оказывает антипролиферативное воздействие на клетки ERα-положительного рака молочной железы и демонстрирует высокую селективность. Антиэстрогенные эффекты THB5T-1 подтверждают его значительный потенциал как селективного ингибитора пути HSP90/ERα/GREB1 и блокатора ERα-опосредованной пролиферации опухолевых клеток.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>HSP90</kwd><kwd>estrogen receptor α</kwd><kwd>antiproliferative agent</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>HSP90</kwd><kwd>рецептор эстрогенов α</kwd><kwd>антипролиферативный агент</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The authors express special gratitude to A. Tishchenko for assistance in organizing biological experiments and conducting immunoblotting, G. Reid and F. Gannon for providing plasmids for transfection, as well as A. Hamidullina and the Center for High-Precision Editing and Genetic Technologies for Biomedicine of the Institute of Gene Biology of the Russian Academy of Sciences for providing equipment (microplate spectrophotometer). This research was partly funded by the Russian Scientific Foundation (analysis of HSP90 signaling pathways; project No. 24-15-00273) and Belarusian Republican Foundation for Fundamental Research (HSP90 inhibitor design and synthesis; project No. Х22MC-030). The protocol of the study was approved by the committee on biomedical ethics of N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.</funding-statement><funding-statement xml:lang="ru">Авторы выражают особую благодарность A. Тищенко за помощь в организации биологических экспериментов и проведении иммуноблоттинга, G. Reid и F. Gannon за предоставление плазмид для трансфекции, а также А. Хамидуллиной и Центру высокоточного редактирования и генетических технологий для биомедицины ФГБУН «Институт биологии гена Российской академии наук» за предоставление оборудования (микропланшетного спектрофотометра). Исследование выполнено при частичной финансовой поддержке Российского научного фонда (анализ сигнальных путей HSP90; проект № 24-15-00273) и Белорусского республиканского фонда фундаментальных исследований (дизайн и синтез ингибитора HSP90; проект № Х22МС-030). Протокол исследования одобрен комитетом по биомедицинской этике ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Zagouri F., Bournakis E., Koutsoukos K. et al. Heat shock protein 90 (hsp90) expression and breast cancer. Pharmaceuticals (Basel) 2012;5(9):1008–20. DOI: 10.3390/ph5091008</mixed-citation><mixed-citation xml:lang="ru">Zagouri F., Bournakis E., Koutsoukos K. et al. Heat shock protein 90 (hsp90) expression and breast cancer. Pharmaceuticals (Basel) 2012;5(9):1008–20. DOI: 10.3390/ph5091008</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Birbo B., Madu E.E., Madu C.O. et al. Role of HSP90 in cancer. Int J Mol Sci 2021;22(19):10317. DOI: 10.3390/ijms221910317</mixed-citation><mixed-citation xml:lang="ru">Birbo B., Madu E.E., Madu C.O. et al. Role of HSP90 in cancer. Int J Mol Sci 2021;22(19):10317. DOI: 10.3390/ijms221910317</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Whitley D., Goldberg S.P., Jordan W.D. Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 1999;29(4):748–51. DOI: 10.1016/s0741-5214(99)70329-0</mixed-citation><mixed-citation xml:lang="ru">Whitley D., Goldberg S.P., Jordan W.D. Heat shock proteins: a review of the molecular chaperones. J Vasc Surg 1999;29(4):748–51. DOI: 10.1016/s0741-5214(99)70329-0</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Schwab M., Multhoff G. A Low membrane Hsp70 expression in tumor cells with impaired lactate metabolism mediates radiosensitization by NVP-AUY922. Front Oncol 2022;12:861266. DOI: 10.3389/fonc.2022.861266</mixed-citation><mixed-citation xml:lang="ru">Schwab M., Multhoff G. A Low membrane Hsp70 expression in tumor cells with impaired lactate metabolism mediates radiosensitization by NVP-AUY922. Front Oncol 2022;12:861266. DOI: 10.3389/fonc.2022.861266</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Li W., Tsen F., Sahu D. et al. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. Int Rev Cell Mol Biol 2013;303:203–35. DOI: 10.1016/b978-0-12-407697-6.00005-2</mixed-citation><mixed-citation xml:lang="ru">Li W., Tsen F., Sahu D. et al. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. Int Rev Cell Mol Biol 2013;303:203–35. DOI: 10.1016/b978-0-12-407697-6.00005-2</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Zhang S., Wang C., Ma B. et al. Mutant p53 drives cancer metastasis via RCP-mediated Hsp90α secretion. Cell Rep 2020;32(1):107879. DOI: 10.1016/j.celrep.2020.107879</mixed-citation><mixed-citation xml:lang="ru">Zhang S., Wang C., Ma B. et al. Mutant p53 drives cancer metastasis via RCP-mediated Hsp90α secretion. Cell Rep 2020;32(1):107879. DOI: 10.1016/j.celrep.2020.107879</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Gougelet A., Bouclier C., Marsaud V. et al. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. J Steroid Biochem Mol Biol 2005;94(1–3):71–81. DOI: 10.1016/j.jsbmb.2005.01.018</mixed-citation><mixed-citation xml:lang="ru">Gougelet A., Bouclier C., Marsaud V. et al. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. J Steroid Biochem Mol Biol 2005;94(1–3):71–81. DOI: 10.1016/j.jsbmb.2005.01.018</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Prodromou C. Mechanisms of Hsp90 regulation. Biochem J 2016;473(16):2439–52. DOI: 10.1042/bcj20160005</mixed-citation><mixed-citation xml:lang="ru">Prodromou C. Mechanisms of Hsp90 regulation. Biochem J 2016;473(16):2439–52. DOI: 10.1042/bcj20160005</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Piven Y.A., Yastrebova M.A., Khamidullina A.I. et al. Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells. Bioorgan Med Chem 2022;53:116521. DOI: 10.1016/j.bmc.2021.116521</mixed-citation><mixed-citation xml:lang="ru">Piven Y.A., Yastrebova M.A., Khamidullina A.I. et al. Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells. Bioorgan Med Chem 2022;53:116521. DOI: 10.1016/j.bmc.2021.116521</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8(4 Suppl.):S55–61. DOI: 10.1016/s1471-4914(02)02316-x</mixed-citation><mixed-citation xml:lang="ru">Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8(4 Suppl.):S55–61. DOI: 10.1016/s1471-4914(02)02316-x</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Piven Yu.A., Scherbakov A.M., Yastrebova M.A. et al. Effective synthesis of novel dihydrobenzisoxazoles bearing the 2-aminothiazole moiety and evaluation of the antiproliferative activity of their acylated derivatives. Org Biomol Chem 2021;19(47):10432–43. DOI: 10.1039/d1ob01614h</mixed-citation><mixed-citation xml:lang="ru">Piven Yu.A., Scherbakov A.M., Yastrebova M.A. et al. Effective synthesis of novel dihydrobenzisoxazoles bearing the 2-aminothiazole moiety and evaluation of the antiproliferative activity of their acylated derivatives. Org Biomol Chem 2021;19(47):10432–43. DOI: 10.1039/d1ob01614h</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Pillai R.N., Ramalingam S.S. Throwing more cold water on heat shock protein 90 inhibitors in NSCLC. J Thorac Oncol 2018;13(4):473–4. DOI: 10.1016/j.jtho.2018.02.010</mixed-citation><mixed-citation xml:lang="ru">Pillai R.N., Ramalingam S.S. Throwing more cold water on heat shock protein 90 inhibitors in NSCLC. J Thorac Oncol 2018;13(4):473–4. DOI: 10.1016/j.jtho.2018.02.010</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Varabyeva N.A., Salnikova D.I., Krymov S.K. et al. Design and synthesis of novel 6,7-dihydrobenzo[d]isoxazol-4(5H)-one derivatives bearing 1,2,3-triazole moiety as potential Hsp90 inhibitors and their evaluation as antiproliferative agents. Chem Select 2024;9(12):e202304812. DOI: 10.1002/slct.202304812</mixed-citation><mixed-citation xml:lang="ru">Varabyeva N.A., Salnikova D.I., Krymov S.K. et al. Design and synthesis of novel 6,7-dihydrobenzo[d]isoxazol-4(5H)-one derivatives bearing 1,2,3-triazole moiety as potential Hsp90 inhibitors and their evaluation as antiproliferative agents. Chem Select 2024;9(12):e202304812. DOI: 10.1002/slct.202304812</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Egorov E.E., Moldaver M.V., Vishniakova Kh.S. et al. Enhanced control of proliferation in telomerized cells. Ontogenez 2007;38(2):105–19.</mixed-citation><mixed-citation xml:lang="ru">Egorov E.E., Moldaver M.V., Vishniakova Kh.S. et al. Enhanced control of proliferation in telomerized cells. Ontogenez 2007;38(2):105–19.</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Iselt M., Holtei W., Hilgard P. The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity. Arzneimittelforschung 1989;39(7):747–9.</mixed-citation><mixed-citation xml:lang="ru">Iselt M., Holtei W., Hilgard P. The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity. Arzneimittelforschung 1989;39(7):747–9.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Ilovaisky A.I., Scherbakov A.M., Chernoburova E.I. et al. Secosteroid diacylhydrazines as novel effective agents against hormone-dependent breast cancer cells. J Steroid biochem Mol Biol 2024;244:106597. DOI 10.1016/j.jsbmb.2024.106597</mixed-citation><mixed-citation xml:lang="ru">Ilovaisky A.I., Scherbakov A.M., Chernoburova E.I. et al. Secosteroid diacylhydrazines as novel effective agents against hormone-dependent breast cancer cells. J Steroid biochem Mol Biol 2024;244:106597. DOI 10.1016/j.jsbmb.2024.106597</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Reid G., Hübner M.R., Métivier R. et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11(3):695–707. DOI: 10.1016/s1097-2765(03)00090-x</mixed-citation><mixed-citation xml:lang="ru">Reid G., Hübner M.R., Métivier R. et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11(3):695–707. DOI: 10.1016/s1097-2765(03)00090-x</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Scherbakov A.M., Komkov A.V., Komendantova A.S. et al. Steroidal pyrimidines and dihydrotriazines as novel classes of anticancer agents against hormone-dependent breast cancer cells. Front Pharmacol 2017;8:979. DOI: 10.3389/fphar.2017.00979</mixed-citation><mixed-citation xml:lang="ru">Scherbakov A.M., Komkov A.V., Komendantova A.S. et al. Steroidal pyrimidines and dihydrotriazines as novel classes of anticancer agents against hormone-dependent breast cancer cells. Front Pharmacol 2017;8:979. DOI: 10.3389/fphar.2017.00979</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Sander T., Freyss J., von Korff M. et al. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J Chem Inf Model 2015;55(2):460–73. DOI: 10.1021/ci500588j</mixed-citation><mixed-citation xml:lang="ru">Sander T., Freyss J., von Korff M. et al. DataWarrior: an open-source program for chemistry aware data visualization and analysis. J Chem Inf Model 2015;55(2):460–73. DOI: 10.1021/ci500588j</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. O’Boyle N.M., Banck M., James C.A. et al. Open babel: an open chemical toolbox. J Cheminform 2011;3:33. DOI: 10.1186/1758-2946-3-33</mixed-citation><mixed-citation xml:lang="ru">O’Boyle N.M., Banck M., James C.A. et al. Open babel: an open chemical toolbox. J Cheminform 2011;3:33. DOI: 10.1186/1758-2946-3-33</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Morris G.M., Huey R., Lindstrom W. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30(16):2785–91. DOI: 10.1002/jcc.21256</mixed-citation><mixed-citation xml:lang="ru">Morris G.M., Huey R., Lindstrom W. et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30(16):2785–91. DOI: 10.1002/jcc.21256</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Alhossary A., Handoko S.D., Mu Y. et al. Fast, accurate, and reliable molecular docking with QuickVina 2. Bioinformatics 2015;31(13):2214–6. DOI: 10.1093/bioinformatics/btv082</mixed-citation><mixed-citation xml:lang="ru">Alhossary A., Handoko S.D., Mu Y. et al. Fast, accurate, and reliable molecular docking with QuickVina 2. Bioinformatics 2015;31(13):2214–6. DOI: 10.1093/bioinformatics/btv082</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">23. Abraham M.J., Murtola T., Schulz R. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015;1–2: 19–25. DOI: 10.1016/j.softx.2015.06.001</mixed-citation><mixed-citation xml:lang="ru">Abraham M.J., Murtola T., Schulz R. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015;1–2: 19–25. DOI: 10.1016/j.softx.2015.06.001</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">24. Sousa da Silva A.W., Vranken W.F. ACPYPE – AnteChamber PYthon Parser interfacE. BMC Res Notes 2012;5:367. DOI: 10.1186/1756-0500-5-367</mixed-citation><mixed-citation xml:lang="ru">Sousa da Silva A.W., Vranken W.F. ACPYPE – AnteChamber PYthon Parser interfacE. BMC Res Notes 2012;5:367. DOI: 10.1186/1756-0500-5-367</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">25. Valdes-Tresanco M.S., Valdes-Tresanco M.E., Valiente P.A. et al. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput 2021;17(10):6281–91. DOI: 10.1021/acs.jctc.1c00645</mixed-citation><mixed-citation xml:lang="ru">Valdes-Tresanco M.S., Valdes-Tresanco M.E., Valiente P.A. et al. gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput 2021;17(10):6281–91. DOI: 10.1021/acs.jctc.1c00645</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">26. Hawkins G.D., Cramer C.J., Truhlar D.G. Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium. J Physical Chem 1996;100(51):19824–39. DOI: 10.1021/jp961710n</mixed-citation><mixed-citation xml:lang="ru">Hawkins G.D., Cramer C.J., Truhlar D.G. Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium. J Physical Chem 1996;100(51):19824–39. DOI: 10.1021/jp961710n</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">27. El-Naggar M., Eldehna W.M., Almahli H. et al. Novel thiazolidinone/thiazolo[3,2-a]benzimidazolone-Isatin conjugates as apoptotic anti-proliferative agents towards breast cancer: one-pot synthesis and in vitro biological evaluation. Molecules (Basel) 2018;23(6):1420. DOI: 10.3390/molecules23061420</mixed-citation><mixed-citation xml:lang="ru">El-Naggar M., Eldehna W.M., Almahli H. et al. Novel thiazolidinone/thiazolo[3,2-a]benzimidazolone-Isatin conjugates as apoptotic anti-proliferative agents towards breast cancer: one-pot synthesis and in vitro biological evaluation. Molecules (Basel) 2018;23(6):1420. DOI: 10.3390/molecules23061420</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">28. Ilovaisky A.I., Scherbakov A.M., Merkulova V.M. et al. Secosteroid-quinoline hybrids as new anticancer agents. J Steroid Biochem molecular Biol 2023;228:106245. DOI: 10.1016/j.jsbmb.2022.106245</mixed-citation><mixed-citation xml:lang="ru">Ilovaisky A.I., Scherbakov A.M., Merkulova V.M. et al. Secosteroid-quinoline hybrids as new anticancer agents. J Steroid Biochem molecular Biol 2023;228:106245. DOI: 10.1016/j.jsbmb.2022.106245</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">29. Supasena W., Muangnoi C., Praengam K. et al. Enhanced selective cytotoxicity of doxorubicin to breast cancer cells by methoxypolyethylene glycol conjugation via a novel beta-thiopropanamide linker. Eur Polymer J 2020;141:110056. DOI: 10.1016/j.eurpolymj.2020.110056</mixed-citation><mixed-citation xml:lang="ru">Supasena W., Muangnoi C., Praengam K. et al. Enhanced selective cytotoxicity of doxorubicin to breast cancer cells by methoxypolyethylene glycol conjugation via a novel beta-thiopropanamide linker. Eur Polymer J 2020;141:110056. DOI: 10.1016/j.eurpolymj.2020.110056</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">30. Duarte D., Nunes M., Ricardo S. et al. Combination of antimalarial and CNS drugs with antineoplastic agents in MCF-7 breast and HT-29 colon cancer cells: biosafety evaluation and mechanism of action. Biomolecules 2022;12(10):1490. DOI: 10.3390/biom12101490</mixed-citation><mixed-citation xml:lang="ru">Duarte D., Nunes M., Ricardo S. et al. Combination of antimalarial and CNS drugs with antineoplastic agents in MCF-7 breast and HT-29 colon cancer cells: biosafety evaluation and mechanism of action. Biomolecules 2022;12(10):1490. DOI: 10.3390/biom12101490</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">31. Tokui K., Adachi H., Waza M. et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 2009;18(5):898–910. DOI: 10.1093/hmg/ddn419</mixed-citation><mixed-citation xml:lang="ru">Tokui K., Adachi H., Waza M. et al. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum Mol Genet 2009;18(5):898–910. DOI: 10.1093/hmg/ddn419</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">32. Kudryavtsev V.A., Khokhlova A.V., Mosina V.A. et al. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: a predictive marker and promising target for radiosensitization. PloS One 2017;12(3):e0173640. DOI: 10.1371/journal.pone.0173640</mixed-citation><mixed-citation xml:lang="ru">Kudryavtsev V.A., Khokhlova A.V., Mosina V.A. et al. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: a predictive marker and promising target for radiosensitization. PloS One 2017;12(3):e0173640. DOI: 10.1371/journal.pone.0173640</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">33. Shimomura A., Yamamoto N., Kondo S. et al. First-in-Human phase i study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Mol Cancer Ther 2019;18(3):531–40. DOI: 10.1158/1535-7163.mct-18-0831</mixed-citation><mixed-citation xml:lang="ru">Shimomura A., Yamamoto N., Kondo S. et al. First-in-Human phase i study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Mol Cancer Ther 2019;18(3):531–40. DOI: 10.1158/1535-7163.mct-18-0831</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">34. Ryan D., Carberry S., Murphy Á.C. et al. Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer. J Transl Med 2016;14(1):196. DOI: 10.1186/s12967-016-0948-z</mixed-citation><mixed-citation xml:lang="ru">Ryan D., Carberry S., Murphy Á.C. et al. Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer. J Transl Med 2016;14(1):196. DOI: 10.1186/s12967-016-0948-z</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">35. Powell L.E., Foster P.A. Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy. Cancer Med 2021;10(8):2812–25. DOI: 10.1002/cam4.3836</mixed-citation><mixed-citation xml:lang="ru">Powell L.E., Foster P.A. Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy. Cancer Med 2021;10(8):2812–25. DOI: 10.1002/cam4.3836</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">36. Yadav M., Singh A.K., Kumar A. et al. An insight to heat shock protein 90: a remedy for multiple problems. Curr Pharm Des 2022;28(32):2664–76. DOI: 10.2174/1381612828666220829120630</mixed-citation><mixed-citation xml:lang="ru">Yadav M., Singh A.K., Kumar A. et al. An insight to heat shock protein 90: a remedy for multiple problems. Curr Pharm Des 2022;28(32):2664–76. DOI: 10.2174/1381612828666220829120630</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">37. Cheng M., Michalski S., Kommagani R. Role for growth regulation by estrogen in breast cancer 1 (GREB1) in hormone-dependent cancers. Int J Mol Sci 2018;19(9):2543. DOI: 10.3390/ijms19092543</mixed-citation><mixed-citation xml:lang="ru">Cheng M., Michalski S., Kommagani R. Role for growth regulation by estrogen in breast cancer 1 (GREB1) in hormone-dependent cancers. Int J Mol Sci 2018;19(9):2543. DOI: 10.3390/ijms19092543</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">38. Qie S., Diehl J.A. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl) 2016;94(12):1313–26. DOI: 10.1007/s00109-016-1475-3</mixed-citation><mixed-citation xml:lang="ru">Qie S., Diehl J.A. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med (Berl) 2016;94(12):1313–26. DOI: 10.1007/s00109-016-1475-3</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">39. De U., Chun P., Choi W.S. et al. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression. Int J Oncol 2014;44(1):167–76. DOI: 10.3892/ijo.2013.2160</mixed-citation><mixed-citation xml:lang="ru">De U., Chun P., Choi W.S. et al. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression. Int J Oncol 2014;44(1):167–76. DOI: 10.3892/ijo.2013.2160</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">40. Piven Y.A., Zinovich V.G., Shcherbakov D.N. et al. Computer-aided design, synthesis and evaluation of new SARS-CoV-2 Mpro inhibitors based on 1,5,6,7-tetrahydro-4H-indazol-4-one scaffold. Med Chem Res 2023;33(1):151–63. DOI: 10.1007/s00044-023-03174-z</mixed-citation><mixed-citation xml:lang="ru">Piven Y.A., Zinovich V.G., Shcherbakov D.N. et al. Computer-aided design, synthesis and evaluation of new SARS-CoV-2 Mpro inhibitors based on 1,5,6,7-tetrahydro-4H-indazol-4-one scaffold. Med Chem Res 2023;33(1):151–63. DOI: 10.1007/s00044-023-03174-z</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">41. Thorn C.F., Oshiro C., Marsh S. et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011;21(7):440–6. DOI: 10.1097/FPC.0b013e32833ffb56</mixed-citation><mixed-citation xml:lang="ru">Thorn C.F., Oshiro C., Marsh S. et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011;21(7):440–6. DOI: 10.1097/FPC.0b013e32833ffb56</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">42. O’Reilly M., Mellotte G., Ryan B. et al. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis 2020;11: 2040622320970354. DOI: 10.1177/2040622320970354</mixed-citation><mixed-citation xml:lang="ru">O’Reilly M., Mellotte G., Ryan B. et al. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis 2020;11: 2040622320970354. DOI: 10.1177/2040622320970354</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">43. Jin H., Wang L., Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 2023;22(3):213–34. DOI: 10.1038/s41573-022-00615-z</mixed-citation><mixed-citation xml:lang="ru">Jin H., Wang L., Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 2023;22(3):213–34. DOI: 10.1038/s41573-022-00615-z</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">44. Kau T.R., Schroeder F., Ramaswamy S. et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003;4(6):463–76. DOI: 10.1016/s1535-6108(03)00303-9</mixed-citation><mixed-citation xml:lang="ru">Kau T.R., Schroeder F., Ramaswamy S. et al. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell 2003;4(6):463–76. DOI: 10.1016/s1535-6108(03)00303-9</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">45. Scherbakov A.M., Bogdanov F.B., Mikhaylova A.L. et al. Targeting AKT kinase in hydroxytamoxifen-resistant breast cancer cells. Med Sci Forum 2023;20(1):4. DOI: 10.3390/IECC2023-14224</mixed-citation><mixed-citation xml:lang="ru">Scherbakov A.M., Bogdanov F.B., Mikhaylova A.L. et al. Targeting AKT kinase in hydroxytamoxifen-resistant breast cancer cells. Med Sci Forum 2023;20(1):4. DOI: 10.3390/IECC2023-14224</mixed-citation></citation-alternatives></ref></ref-list></back></article>
